Orbimed Advisors LLC Aeglea Bio Therapeutics, Inc. Transaction History

Orbimed Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.5 - $2.66 $579,451 - $3.08 Million	-1,158,903 Reduced 39.2%	1,797,221 $908,000
Q4 2021 Feb 14, 2022	SELL	$3.5 - $8.42 $3.71 Million - $8.92 Million	-1,059,400 Reduced 26.38%	2,956,124 $14 Million
Q2 2020 Aug 14, 2020	BUY	$4.01 - $11.04 $4.61 Million - $12.7 Million	1,150,000 Added 40.13%	4,015,524 $37.1 Million
Q3 2019 Nov 14, 2019	BUY	$6.42 - $9.0 $4.49 Million - $6.3 Million	700,000 Added 32.32%	2,865,524 $22 Million
Q3 2018 Nov 14, 2018	BUY	$8.24 - $11.0 $2.47 Million - $3.3 Million	300,000 Added 16.08%	2,165,524 $20.7 Million
Q2 2018 Aug 14, 2018	BUY	$7.87 - $10.89 $3.12 Million - $4.31 Million	396,000 Added 26.95%	1,865,524 $19.7 Million
Q3 2017 Nov 14, 2017	BUY	$2.91 - $4.93 $4.28 Million - $7.24 Million	1,469,524	1,469,524 $7.24 Million

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.